Genocea announces close of $35 million Series B venture financing round

March 16, 2017

As chief medical officer, Dr. Hetherington will be responsible for all clinical, medical and regulatory activities. He brings to Genocea more than 25 years of experience in clinical drug development and academic medicine. Prior to joining Genocea, Dr. Hetherington was senior vice president, clinical and regulatory affairs at Icagen, a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets. Earlier in his career, Dr. Hetherington was vice president, clinical development and chief medical officer at Inhibitex and served in positions of increasing responsibility in clinical drug development at GlaxoSmithKline and Glaxo Wellcome, where he made significant contributions to several clinical development programs, including the currently marketed pharmaceuticals Ziagen?, Trizivir? and Agenerase?. Dr. Hetherington currently serves as the industry representative to the Vaccines and Related Blood Products Advisory Committee of the U.S. Food and Drug Administration.

SOURCE Genocea Biosciences Inc.,

©2017 -